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uman Stem Cells
or Heart Failure Treatment
eady for Prime Time?*
ianluigi Condorelli, MD, PHD,†‡
aniele Catalucci, PHD†‡
an Diego, California; and Milan, Italy
he possibility of replacing the failing myocardium with
ewly generated tissue is challenging many researchers in
he field of cardiovascular medicine. During the last decade,
any types of “stem” cells have been used in an attempt to
roduce differentiated cardiac myocytes (CMs). Among the
arious types of putative cardiac progenitor cells, mesenchy-
al, hematopoietic, and local cardiac cells have been tested
or their potential as a source of CM progenitors. However,
ata obtained using these cells are not univocal. For in-
tance, the highly efficient differentiation rate of hemato-
oietic (1) and mesenchymal (2) stem cells toward CMs
bserved in initial studies was not subsequently confirmed
3). Rigorous methodologies, including genetically modified
ouse models that permit discrimination between cell
usion and true differentiation, suggested that the few
ifferentiation events after myocardial injection of hemato-
oietic stem cells (HSCs) could be ascribed to the fusion
etween pre-existing myocytes and transplanted cells (3).
See page 1884
he small yield of HSCs differentiating into CMs may be at
he basis of the modest improvement of cardiac function by
utologous bone marrow cell injection after myocardial
nfarction (MI) (4). Moreover, production of growth factors
ith antiapoptotic effect by injected cells on host myocar-
ium was suggested to be responsible for the slight func-
ional improvement (5,6).
Previous studies have described various types of local
ouse and human cardiac stem cells (7), which are still in
he process of being characterized. More recently, other
Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.
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inistries of University Research (MUR) and Health.ources of differentiated CMs have been described, including
permatogonial cells derived from adult testis (8). Interest-
ngly, the use of spermatogonial cells provides a relevant
lternative to embryonic stem cells (ESCs) and may over-
ome current legal and ethical issues that limit the potential
herapeutic use of embryonic cells in many countries.
Mouse embryonic stem cells (mESCs) were originally
escribed 25 years ago (9). Since then, a multitude of
ell-established cell culture techniques and genetic manip-
lation with viruses or homologous recombination has been
eveloped. Mouse embryonic stem cells derive from the first
ew cellular divisions of the zygote (10) and can spontane-
usly differentiate into beating CMs (11) as well as other
ell types. Embryonic stem cells mature in vitro within
o-called embryoid bodies (EBs), teratoma-like structures,
hich contain cells originating from all 3 embryonic layers,
amely mesoderm, ectoderm, and endoderm (11). Genera-
ion of “bulk” cultures of endothelial stem-CMs has been
btained as a result of a significant increase in the yield of
ESC-derived CMs from pluripotent mESCs (12). This
mprovement has been achieved through genetic selections
btained by transfecting mESCs with a reporter gene
ontaining a drug-resistance marker (an enzyme that me-
abolizes a toxic drug) under the expression control of a
ardiac-specific promoter. After injection, mESC-derived
Ms integrate in the host myocardium and form gap
unctions with hosting CMs, which results in significantly
mproved myocardial contraction in experimental models of
eart failure (12). Interestingly, mESC-derived CMs also
mproved cardiac function in a xenograph sheep model of
eart failure (13).
In the late 1990s, human embryonic stem cells (hESCs)
ame into play. These cells originate from frozen embryos
et aside from in vitro fertilization procedures (14). A
umber of cell lines generated from different institutions
hroughout the world are today available, with a differenti-
tion potential that varies from cell line to cell line. Kehat et
l. (15) provided the first evidence that hESCs can generate
ifferentiated CMs, expressing markers of cardiac differen-
iation and showing excitation-contraction coupling. The
ifferentiation process is not straightforward: cells are grown
n a feeder-layer of fetal fibroblasts, which are usually of
ouse origin, while differentiation into EBs, which takes
eeks to complete, is induced by seeding small drops of cells
n plastic support (15). Within each EB, an area of
pontaneous contraction, containing differentiated myo-
ytes, can be more or less extended. The spontaneous
epolarization of these cells was further proved by Gep-
tein’s group (16), who also show that, thanks to their
acemaker property, these cells could be used for therapeu-
ic purposes in a pig model of atrioventricular block. For
eart failure treatment, a relatively large number of cells are
eeded. In this issue of the Journal, Caspi et al. (17) demon-
trate that grafting of hESC-derived myocytes improves car-
iac function in a rat model of heart failure after MI.
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November 6, 2007:1894–5 Editorial CommentThe authors injected undifferentiated hESC, hESC-
Ms, or non–hESC-CM derivatives in cyclosporine-
mmunosuppressed rat myocardium after MI. They found
hat transplantation of undifferentiated hESCs resulted in
he formation of teratoma-like structures, thus indicating
hat the cardiac environment does not enhance hESC
ardiomyogenesis. This phenomenon was prevented by
rafting of ex vivo–differentiated hESC-CMs. The grafted
Ms, tracked by a combination of elegant cellular and
olecular technologies, survived, proliferated, matured,
ligned, and formed gap junctions within the transplanted
yocardium. Functionally, animals injected with saline or
onmyocyte hESC derivatives demonstrated significant left
entricular dilatation and functional deterioration, whereas
rafting of hESC-CMs attenuated the remodeling process.
he achieved improvement in cardiac function was depen-
ent on hESC-CMs, demonstrated by deterioration of
ardiac function after grafting of non–hESC-CMs. This
ndicates that the force generated by the transplanted
ESC-CM is responsible for functional amelioration, not
ynthesis of growth factors released by grafted cells. Of note,
aspi et al. (17) found that these cells are devoid of
rrhythmogenic potential, a complication that hampers the
linical use of autologous skeletal muscle cell grafting in
eart failure (18).
Overall, the current study represents a milestone in this
rea of investigation. Of course, many issues still need to be
esolved before the clinical use of hESC-CMs becomes a
eality. First, it is critical to increase the yield of hESC-
Ms. Caspi et al. (17) obtained a significant improvement
f cardiac function using a relatively small number of cells,
onsidering that cells were selected from the beating part of
Bs. This is an encouraging result, but upscaling of the
rocedure is still a fundamental requirement if large areas of
he myocardium have to be savaged. A better knowledge
f the biochemistry of the differentiation process of
ESC-CM will certainly improve the technical conditions
ecessary for achieving this task. Secondly, the immunolog-
cal mismatch between donor and grafted tissues represents
nother serious limitation. Human endothelial stem cells are
ess immunogenic that adult cells because they express low
evels of the class I major histocompatibility complex (19).
ne solution to the donor–recipient mismatch problem
ould be the banking of a large numbers of frozen hESC
ines, matching as many potential recipient individuals as
ossible, an approach similar to the current procedures for
one marrow transplantation. Another solution could be
uclear transfer, a technique in which nuclei from an adultndividual, in this case the recipient, substitute oocyteuclei. Matching zygotes and hESC lines are then devel-
ped, a technique named “therapeutic” cloning (10).
The next couple of years will tell us whether hESC-CMs
an be considered a realistic therapeutic option in heart
ailure.
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